Last reviewed · How we verify
Ziresovir 125 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Ziresovir 125 mg (Ziresovir 125 mg) — Shanghai Ark Biopharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ziresovir 125 mg TARGET | Ziresovir 125 mg | Shanghai Ark Biopharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ziresovir 125 mg CI watch — RSS
- Ziresovir 125 mg CI watch — Atom
- Ziresovir 125 mg CI watch — JSON
- Ziresovir 125 mg alone — RSS
Cite this brief
Drug Landscape (2026). Ziresovir 125 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/ziresovir-125-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab